Skip to content

he Efficacy and Safety of Remimazolam Besylate in the Withdrawal of Invasive Mechanical Ventilation in Patients with Severe Pneumonia: A Multicenter, Prospective, Observational Study

he Efficacy and Safety of Remimazolam Besylate in the Withdrawal of Invasive Mechanical Ventilation in Patients with Severe Pneumonia: A Multicenter, Prospective, Observational Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103955
Enrollment
Unknown
Registered
2025-06-09
Start date
2025-06-15
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe pneumonia

Interventions

Sponsors

The Affiliated Hospital of Jining Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with a clear diagnosis of severe pneumonia who have undergone endotracheal intubation and invasive mechanical ventilation. 2. Patients with a definite improvement in the primary disease that led to respiratory failure, and who are to be evacuated from mechanical ventilation and removed from the endotracheal intubation. 3. Meet the weaning criteria of the "Guidelines for the Clinical Application of Mechanical Ventilation" of the Critical Care Medicine Branch of the Chinese Medical Association, such as: oxygenation index: PaO2/FiO2>=150 to 300 mmHg; PEEP = 7.25, and for COPD: pH > 7.30, FiO2 50 mmHg. Hemodynamically stable, no dynamic changes in myocardial ischemia, no obvious clinical hypotension (no vasoactive drug treatment or only small doses of drugs, such as dopamine or dobutamine <5~10µg/kg/min). 4. Patients who are to be sedated with remimazolam tosylate or dexmedetomidine during weaning.

Exclusion criteria

Exclusion criteria: 1. Age> 80 years old or 35; 3. Pregnant and lactating women; 4. Patients with severe hepatic and renal insufficiency; 5. New York class of cardiac function grade IV; 6. Patients who are not using remimazolam tosylate or dexmedetomidine or concomitantly; 7. Refusal of the patient or his/her agent to participate in this study.

Design outcomes

Primary

MeasureTime frame
Satisfaction rate of sedation;

Countries

China

Contacts

Public ContactXie Xuemeng

The Affiliated Hospital of Jining Medical College

756252748@qq.com+86 537 290 3633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026